GEN1286 looks dead, though MCLA-129 continues for now.

And the company says it won’t need to carry out another trial.

Takeda picked up IBI363 for $1.2bn, and now Innovent advances IBI3026.

A fresh licensing deal tidies up years of work between the two companies.

And that could affect the drug's third-line accelerated approval. 

The “next-gen” PF-07985045 is gone, but the group has another pan-KRAS shot.